Business Context and Reporting Period
This Form 8-K, filed on January 5, 2012, reports events occurring on December 29 and 30, 2011, for Manhattan Pharmaceuticals, Inc. (the "Company"). The filing details a transformative Exchange Transaction with TG Therapeutics, Inc. ("TG") and Opus Point Partners, LLC ("Opus"), effectively repositioning the Company's asset base and leadership. The Company also completed the initial closing of a private equity offering during this period.
Key Financial Metrics and Capital Structure
- Capital Raise: The Company completed the initial closing of an offering on December 30, 2011, issuing 277,285,633 shares of common stock at $0.04 per share, generating gross proceeds of approximately $11.09 million.
- Warrants Issued: Investors received warrants to purchase 69,321,424 shares of common stock at an exercise price of $0.04 per share, exercisable for five years.
- Debt Conversion: A loan of $55,270.68 provided by Opus on December 19, 2011, was converted into 2,763 shares of Series A Preferred Stock.
- Preferred Stock Issuance: Opus received 281,250 shares of Series A Preferred Stock in exchange for its TG common stock holdings. Additional restricted shares were issued to Michael S. Weiss (112,500 shares) and Sean A. Power (16,875 shares).
- Liquidity: The filing does not provide specific cash balance figures or liquidity ratios, but the $11.09 million in gross proceeds indicates a significant infusion of capital.
Material Changes Versus Prior Period
- Asset Acquisition: The Company acquired the assets and operations of TG Therapeutics, Inc. through an exchange of stock, shifting its focus to TG's therapeutic pipeline.
- Capital Structure: The Company created a new class of Series A Preferred Stock with a liquidation preference of $20 per share, ranking senior to common stock. Each preferred share is convertible into 500 shares of common stock.
- Ownership: Significant ownership changes occurred as Opus and key TG executives exchanged their TG holdings for Manhattan Pharmaceuticals preferred stock.
Guidance, Management Commentary, and Risks
- Management Changes: Effective December 29, 2011, the Board underwent a complete turnover. Douglas Abel, David C. Shimko, Richard Steinhart, and Michael McGuinness resigned. Michael S. Weiss was appointed Executive Chairman, Interim CEO, and President. Sean A. Power was appointed CFO, Treasurer, and Secretary.
- Related Party Transactions: The placement agent for the offering, National Securities Corporation, is an affiliate of National Holdings, in which CEO Michael S. Weiss beneficially owns 23.6%. Opus and National Securities also share a 50/50 joint venture in the investment banking division managing the offering. Mr. Weiss and Dr. Lindsay A. Rosenwald invested approximately $300,000 and $600,000, respectively, in the offering.
- Regulatory Risks: The securities issued in the offering were sold without registration under the Securities Act of 1933, relying on Section 4(2) and Regulation D exemptions. These securities cannot be resold in the U.S. absent registration or an applicable exemption.
- Future Actions: The Company intends to amend its Certificate of Incorporation or execute a reverse stock split to ensure sufficient authorized shares for the conversion of Preferred Stock.
Investor Verification Checklist
- Verify the final terms of the Exchange Transaction Agreement and the specific assets/liabilities transferred from TG Therapeutics.
- Confirm the status of the Company's authorized share count and the timeline for the amendment to the Certificate of Incorporation required for Preferred Stock conversion.
- Review the full financial statements of TG Therapeutics, which are not included in this filing but are due within 71 days.
- Assess the impact of the related-party fees paid to National Securities Corporation, including the 10% cash commission, 10% warrant commission, and $150,000 advisory fee.
- Monitor the registration status of the unregistered securities issued in the December 30 offering to determine when they become freely tradable.